Centre Hospitalier Prive Saint-Gregoire

At Centre Hospitalier Prive Saint-Gregoire, clinical trials in digestive system diseases focus on major cancers such as colorectal cancer, pancreatic adenocarcinoma, ampullary adenocarcinoma, and metastatic oeso-gastric adenocarcinoma. The research is centered on improving treatment effectiveness, refining adjuvant and first-line strategies, and testing new combinations that may better control advanced disease.

• Testing new treatment approaches for colorectal cancer and rectal cancer
• Evaluating therapies for pancreatic adenocarcinoma and ampullary adenocarcinoma
• Studying options for metastatic oeso-gastric adenocarcinoma and other advanced gastrointestinal cancers

Several studies also explore how biomarkers and response markers can help guide treatment selection and improve outcomes for patients with difficult-to-treat digestive cancers.

This site has a strong focus on male urogenital diseases, especially prostate cancer in its localized, metastatic, and castration-resistant forms, as well as bladder cancer. The trials aim to improve survival, delay progression, and identify better ways to match treatment intensity to disease risk.

• Studying new strategies for metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
• Evaluating treatment approaches for high-risk localized prostate cancer and unfavorable intermediate-risk prostate cancer
• Testing therapies for high-risk non-muscle-invasive bladder cancer and locally advanced or metastatic urothelial cancer

Research in this area includes hormone-based therapies, targeted treatments, and bladder-preserving approaches designed to improve disease control while supporting patient quality of life.

Clinical research in neoplasms at this hospital includes several studies in breast cancer, particularly ER-positive and HER2-negative disease. These trials are exploring ways to personalize therapy, reduce unnecessary treatment, and improve long-term recurrence prevention.

• Assessing endocrine-based strategies for metastatic breast cancer and early-stage disease
• Testing treatment de-escalation in low-risk luminal breast cancer
• Exploring biomarker-guided use of newer therapies in HR-positive, HER2-low metastatic breast cancer

The overall goal is to refine treatment selection so that patients receive therapies that are both effective and appropriate for their individual risk profile.

The site also conducts trials in head and neck squamous cell carcinoma, including recurrent, metastatic, and resected disease. These studies are aimed at improving outcomes after surgery or radiotherapy and at finding better systemic options for advanced cancer.

• Evaluating new combinations for recurrent or metastatic head and neck squamous cell carcinoma
• Studying treatment strategies after surgery for resected squamous cell carcinoma of the head and neck
• Testing approaches that combine immunotherapy with radiotherapy to improve disease control

These trials reflect a broader effort to strengthen both local and systemic treatment for patients with aggressive head and neck cancers.

Beyond its main cancer programs, Centre Hospitalier Prive Saint-Gregoire is involved in research on selected advanced tumors and supportive surgical care. This includes studies in non-small cell lung cancer, endometrial cancer, brain metastases, and incisional hernia, with a mix of treatment and symptom-focused objectives.

• Improving disease control in locally advanced unresectable non-small cell lung cancer and advanced endometrial cancer
• Testing ways to relieve symptoms from brain radionecrosis after treatment for brain metastases
• Evaluating a surgical approach to reduce complications in large incisional hernia repair

Overall, the research portfolio combines precision oncology, immunotherapy, and supportive care studies to address both cancer control and treatment-related complications.